Total Payments
$639,378
2024 Payments
$105,999
Companies
34
Transactions
689
Medicare Patients
700
Medicare Billing
$212,935
Payment Breakdown by Category
Other$354,895 (55.5%)
Consulting$198,073 (31.0%)
Travel$50,913 (8.0%)
Food & Beverage$22,183 (3.5%)
Research$13,022 (2.0%)
Education$292.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $332,790 | 125 | 52.0% |
| Consulting Fee | $198,073 | 57 | 31.0% |
| Travel and Lodging | $50,913 | 141 | 8.0% |
| Food and Beverage | $22,183 | 344 | 3.5% |
| Honoraria | $18,604 | 6 | 2.9% |
| Unspecified | $13,022 | 10 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,500 | 2 | 0.5% |
| Education | $292.26 | 4 | 0.0% |
Payments by Type
General
$626,356
679 transactions
Research
$13,022
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138,832 | 122 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $112,716 | 104 | $0 (2024) |
| ABBVIE INC. | $87,907 | 109 | $0 (2024) |
| Amgen Inc. | $80,846 | 100 | $0 (2024) |
| SOBI, INC | $34,568 | 17 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $31,615 | 37 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $30,726 | 37 | $0 (2024) |
| Dova Pharmaceuticals | $20,547 | 12 | $0 (2021) |
| GENZYME CORPORATION | $18,353 | 9 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $17,751 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $105,999 | 106 | Alexion Pharmaceuticals, Inc. ($30,874) |
| 2023 | $78,183 | 81 | Novartis Pharmaceuticals Corporation ($26,475) |
| 2022 | $85,816 | 83 | ABBVIE INC. ($18,513) |
| 2021 | $85,484 | 68 | AbbVie Inc. ($21,492) |
| 2020 | $45,566 | 39 | Celgene Corporation ($10,907) |
| 2019 | $88,778 | 103 | AbbVie, Inc. ($30,867) |
| 2018 | $78,475 | 111 | Novartis Pharmaceuticals Corporation ($26,375) |
| 2017 | $71,077 | 98 | Novartis Pharmaceuticals Corporation ($30,861) |
All Payment Transactions
689 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Honoraria | In-kind items and services | $2,744.00 | General |
| Category: HEMATOLOGY | ||||||
| 12/13/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $114.48 | General |
| Category: HEMATOLOGY | ||||||
| 12/13/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $85.00 | General |
| Category: HEMATOLOGY | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $30.39 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| Category: Immunology | ||||||
| 12/09/2024 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $112.71 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $83.99 | General |
| Category: Immunology | ||||||
| 12/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Consulting Fee | Cash or cash equivalent | $1,012.50 | General |
| Category: Immunology | ||||||
| 12/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $94.55 | General |
| Category: Immunology | ||||||
| 12/07/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug), VYXEOS, Defitelio | Food and Beverage | In-kind items and services | $123.12 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/07/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $94.06 | General |
| Category: Oncology | ||||||
| 11/29/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $275.00 | Research |
| Study: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) • Category: ONCOLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $39.52 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $843.95 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $36.17 | General |
| Category: Oncology | ||||||
| 11/15/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $27.37 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $121.83 | General |
| Category: Rare Disease | ||||||
| 11/09/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $11,634.00 | General |
| 11/09/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 11/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $49.72 | General |
| 11/09/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $42.18 | General |
| 10/09/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: Oncology | ||||||
| 10/07/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $31.98 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/04/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
| CLNP023C12302 | Novartis Pharmaceuticals Corporation | $1,247 | 1 |
| CMBG453B12201 | Novartis Pharmaceuticals Corporation | $1,084 | 1 |
| A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T) | ABBVIE INC. | $865.47 | 3 |
| CLNP023C12302 - APPLY- PNH | Novartis Pharmaceuticals Corporation | $692.51 | 1 |
| A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) | ABBVIE INC. | $275.00 | 1 |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | ABBVIE INC. | $21.71 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 169 | 577 | $180,302 | $49,529 |
| 2022 | 5 | 194 | 734 | $196,273 | $62,661 |
| 2021 | 5 | 175 | 584 | $150,457 | $47,559 |
| 2020 | 4 | 162 | 657 | $176,678 | $53,186 |
Total Patients
700
Total Services
2,552
Medicare Billing
$212,935
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 102 | 387 | $99,072 | $31,000 | 31.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 159 | $69,033 | $15,201 | 22.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $10,026 | $2,731 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 13 | $2,171 | $596.55 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 90 | 389 | $99,584 | $32,410 | 32.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 51 | 286 | $77,506 | $24,779 | 32.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $7,241 | $2,029 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 15 | 15 | $6,765 | $1,731 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 25 | 31 | $5,177 | $1,713 | 33.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 261 | $66,816 | $22,061 | 33.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 40 | 218 | $59,078 | $18,058 | 30.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 36 | 53 | $8,851 | $2,972 | 33.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 22 | 22 | $9,922 | $2,606 | 26.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 30 | $5,790 | $1,862 | 32.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 62 | 345 | $93,495 | $31,556 | 33.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 67 | 279 | $71,424 | $18,636 | 26.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 22 | 22 | $9,922 | $2,498 | 25.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 11 | 11 | $1,837 | $495.46 | 27.0% |
About Dr. Vinod Pullarkat, M.D
Dr. Vinod Pullarkat, M.D is a Hematology healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164433645.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vinod Pullarkat, M.D has received a total of $639,378 in payments from pharmaceutical and medical device companies, with $105,999 received in 2024. These payments were reported across 689 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($332,790).
As a Medicare-enrolled provider, Pullarkat has provided services to 700 Medicare beneficiaries, totaling 2,552 services with total Medicare billing of $212,935. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Duarte, CA
- Active Since 08/10/2006
- Last Updated 11/27/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1164433645
Products in Payments
- Nplate (Biological) $80,482
- DEFITELIO (Drug) $67,574
- PROMACTA (Drug) $49,399
- Defitelio (Drug) $37,911
- VENCLEXTA (Drug) $36,499
- Doptelet (Drug) $35,244
- REBLOZYL (Biological) $20,566
- ONCASPAR (Drug) $20,313
- DOPTELET (Drug) $19,871
- Rezlidhia (Drug) $17,726
- Venclexta (Drug) $16,121
- Fabhalta (Drug) $8,559
- EXJADE (Drug) $7,186
- Reblozyl (Drug) $6,819
- VENCLEXTA (Biological) $6,429
- VYXEOS (Drug) $6,403
- ASPARLAS (Drug) $6,105
- BESPONSA (Biological) $6,066
- Tibsovo (Drug) $4,307
- Imbruvica (Drug) $3,300
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Duarte
Guido Marcucci, M.d, M.D
Hematology — Payments: $176,185
Hematology $176,185
Alex Herrera, Md, MD
Hematology — Payments: $165,071
Hematology $165,071
Dr. Joseph Chao, M.d, M.D
Hematology — Payments: $152,551
Hematology $152,551
John Baird, Md, MD
Hematology — Payments: $48,735
Hematology $48,735
Dr. Idoroenyi Amanam, M.d, M.D
Hematology — Payments: $22,530
Hematology $22,530
Dr. Swetha Thiruvengadam, M.d, M.D
Hematology — Payments: $21,889
Hematology $21,889